scholarly journals P81.01 Efficacy and Safety of Camrelizumab in Patients with Advanced Lung Cancer: A Multicentre, Prospective, Observational Study.

2021 ◽  
Vol 16 (3) ◽  
pp. S650
Author(s):  
Y.Q. Shu
Keyword(s):  
Lung Cancer ◽  
Observational Study ◽  
Prospective Observational Study ◽  
Advanced Lung Cancer ◽  
Efficacy And Safety

Nutritional status in patients with advanced lung cancer undergoing chemotherapy: a prospective observational study

2019 ◽  
Vol 72 (7) ◽  
pp. 1225-1230 ◽  
Author(s):  
Tie Lin ◽  
Jing Yang ◽  
Xuan Hong ◽  
ZhaoYang Yang ◽  
Ting Ge ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Observational Study ◽  
Nutritional Status ◽  
Prospective Observational Study ◽  
Advanced Lung Cancer

scholarly journals What are the barriers to the completion of a home-based rehabilitation programme for patients awaiting surgery for lung cancer: a prospective observational study

BMJ Open ◽  
2021 ◽  
Vol 11 (2) ◽  
pp. e041907
Author(s):  
Heloise Catho ◽  
Sebastien Guigard ◽  
Anne-Claire Toffart ◽  
Gil Frey ◽  
Thibaut Chollier ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Observational Study ◽  
Prospective Observational Study ◽  
Living Alone ◽  
Chronic Obstructive ◽  
Obstructive Pulmonary Disease ◽  
Factors Associated ◽  
Home Based ◽  
Registration Number

ObjectivesHome-based rehabilitation programmes (H-RPs) could facilitate the implementation of pulmonary rehabilitation prior to resection for non-small cell lung cancer (NSCLC), but their feasibility has not been evaluated. The aim of this study was to identify determinants of non-completion of an H-RP and the factors associated with medical events occurring 30 days after hospital discharge.DesignA prospective observational study.InterventionAll patients with confirmed or suspected NSCLC were enrolled in a four-component H-RP prior to surgery: (i) smoking cessation, (ii) nutritional support, (iii) physiotherapy (at least one session/week) and (iv) home cycle-ergometry (at least three times/week).OutcomesThe H-RP was defined as ‘completed’ if the four components were performed before surgery.ResultsOut of 50 patients included, 42 underwent surgery (80% men; median age: 69 (IQR 25%–75%; 60–74) years; 64% Chronic Obstructive Pulmonary Disease (COPD); 29% type 2 diabetes). Twenty patients (48%) completed 100% of the programme. The median (IQR) duration of the H-RP was 32 (19; 46) days. Multivariate analysis showed polypharmacy (n=24) OR=12.2 (95% CI 2.0 to 74.2), living alone (n=8) (single vs couple) OR=21.5 (95% CI 1.4 to >100) and a long delay before starting the H-RP (n=18) OR=6.24 (95% CI 1.1 to 36.6) were independently associated with a risk of non-completion. In univariate analyses, factors associated with medical events at 30 days were H-RP non-completion, diabetes, polypharmacy, social precariousness and female sex.ConclusionFacing multiple comorbidities, living alone and a long delay before starting the rehabilitation increase the risk of not completing preoperative H-RP.Trial registration numberNCT03530059.

scholarly journals Efficacy and Safety of Ipilimumab plus Chemotherapy for Advanced Lung Cancer: A Systematic Review and Meta-Analysis

2018 ◽  
Vol 9 (23) ◽  
pp. 4556-4567 ◽  
Author(s):  
Hongman Zhang ◽  
Jie Shen ◽  
Lilan Yi ◽  
Wei Zhang ◽  
Peng Luo ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Systematic Review ◽  
Meta Analysis ◽  
Advanced Lung Cancer ◽  
Efficacy And Safety

scholarly journals Out-patient high-dose-rate endobronchial brachytherapy for palliation of lung cancer: an observational study

2016 ◽  
Vol 67 (3) ◽  
Author(s):  
A. Scarda ◽  
M. Confalonieri ◽  
C. Baghiris ◽  
S. Binato ◽  
R. Mazzarotto ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Observational Study ◽  
Dose Rate ◽  
Malignant Tumour ◽  
High Dose Rate ◽  
Advanced Lung Cancer ◽  
High Dose ◽  
End Of Treatment ◽  
Co Morbidity ◽  
Central Airway

Background and Aim. Out-patient high-dose-rate endobronchial brachytherapy (HDREB) is a possible option in the palliation of symptoms in patients with advanced lung cancer, but literature data is limited and the technique is still under development in Italy. Our aim was to evaluate safety and effectiveness of out-patient HDREB for palliation of malignant endobronchial tumours in the context of a multidisciplinary approach. Methods. Out-patient HDREB sessions were scheduled at weekly intervals (500-1000 cGy per session) with prior Diodi-laser resection in some cases. Response was assessed bronchoscopically, clinically and functionally at the end of treatment and one month after the last HDREB session. Inclusion criteria was: histological evidence of malignant tumour not susceptible to surgical treatment for extension or co-morbidity. Results. 150 outpatient HDREB sessions were carried out on consecutive 35 patients (mean age 69 yrs, M/F 29/6) with symptoms due to central airway obstruction. A shortterm endoscopic response was observed in 15/28 patients. After delivering 2000 cGy dyspnoea decreased significantly. After one month cough decreased and haemoptysis disappeared. Palliation was obtained in all patients except one during. Lung function tests did not significantly improve after HDREB. No fatal complication occurred. A temporary radiation bronchitis was observed in six patients. Conclusions. This non-comparative, prospective observational study showed a palliative response of HDREB in most of patients with advanced endoluminal lung cancer. The safety of the procedure was good and the rate of non-fatal serious complications was very low.

Sign in / Sign up

Export Citation Format

Share Document